Jean-Damien Combes1, Isabelle Heard2,3, Isabelle Poizot-Martin4,5, Ana Canestri6, Annie Lion7, Lionel Piroth8,9, Jean-Michel Didelot10, Tristan Ferry11, Olivier Patey12, Lucie Marchand13, Jean-Francois Flejou14,15, Gary M Clifford1, Isabelle Etienney16. 1. International Agency for Research on Cancer, Lyon. 2. Centre National de Référence des HPV, Institut Pasteur, Paris. 3. Hôpital Tenon, AP-HP, Paris. 4. Service d'Immuno-Hématologie Clinique, Université Aix Marseille, APHM Sainte-Marguerite, Marseille. 5. Inserm U912 (SESSTIM), Marseille. 6. Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, AP-HP, Paris. 7. Service des Maladies de l'Appareil Digestif, CHU Pontchaillou, Rennes. 8. Département d'Infectiologie, CHU de Dijon. 9. INSERM CIC 1432, Université de Bourgogne, Dijon. 10. Département d'Hépato-Gastroentérologie, CHU Saint Eloi et Université de Montpellier, Montpellier. 11. Département d'Infectiologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon. 12. Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Villeneuve-Saint-Georges, Villeneuve-Saint-Georges. 13. ANRS (France Recherche Nord et Sud Sida-HIV et Hépatites), Paris. 14. Service d'Anatomie et Cytologie Pathologiques, Hôpital Saint-Antoine, GH HUEP, AP-HP, Paris. 15. Faculté de Médecine Sorbonne Université, Paris. 16. Service de Proctologie Médico-Interventionnelle, Groupe Hospitalier Diaconesses Croix-Saint-Simon, Paris, France.
Abstract
Background: We assessed prevalence and risk factors for anal human papillomavirus (HPV) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM), who are at high-risk of HPV-related anal cancer. Methods: APACHES is a multicentric, prospective study of anal HPV infection and lesions in HIV-positive MSM aged ≥35 years. At baseline, participants underwent anal swabs for HPV and cytology, plus high-resolution anoscopy. High-risk HPV (HR-HPV) was tested by Cobas4800, with genotyping of HR-HPV positives by PapilloCheck. Results: Among 490 participants, prevalence of HPV16 and HR-HPV was 29% and 70%, respectively, and did not differ significantly by age, sexual behavior, or markers of HIV or immune deficiency. Smoking was the only, albeit weak (odds ratio, 1.8; 95% confidence interval, 1.2-2.7), predictor of HR-HPV. High-risk HPV and HPV16 prevalence increased strongly with anal diagnosis severity, both by worse cytological/histological (composite) diagnosis at APACHES baseline and worse historical diagnosis. HPV16 rose from 19% among participants who were negative for lesions to 63% among participants with high-grade lesions. In contrast, non-HPV16 HR-HPVs were less prevalent in high-grade (37%) than negative (64%) composite diagnosis, and their causal attribution was further challenged by multiple HPV infections. Conclusions: Human papillomavirus 16 is ubiquitously frequent among human immunodeficiency virus -positive men having sex with men, and more strongly associated with high-grade anal lesions than other high-risk types, confirming it as a target for anal cancer prevention.
Background: We assessed prevalence and risk factors for anal human papillomavirus (HPV) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM), who are at high-risk of HPV-related anal cancer. Methods: APACHES is a multicentric, prospective study of anal HPV infection and lesions in HIV-positive MSM aged ≥35 years. At baseline, participants underwent anal swabs for HPV and cytology, plus high-resolution anoscopy. High-risk HPV (HR-HPV) was tested by Cobas4800, with genotyping of HR-HPV positives by PapilloCheck. Results: Among 490 participants, prevalence of HPV16 and HR-HPV was 29% and 70%, respectively, and did not differ significantly by age, sexual behavior, or markers of HIV or immune deficiency. Smoking was the only, albeit weak (odds ratio, 1.8; 95% confidence interval, 1.2-2.7), predictor of HR-HPV. High-risk HPV and HPV16 prevalence increased strongly with anal diagnosis severity, both by worse cytological/histological (composite) diagnosis at APACHES baseline and worse historical diagnosis. HPV16 rose from 19% among participants who were negative for lesions to 63% among participants with high-grade lesions. In contrast, non-HPV16 HR-HPVs were less prevalent in high-grade (37%) than negative (64%) composite diagnosis, and their causal attribution was further challenged by multiple HPV infections. Conclusions: Human papillomavirus 16 is ubiquitously frequent among human immunodeficiency virus -positive men having sex with men, and more strongly associated with high-grade anal lesions than other high-risk types, confirming it as a target for anal cancer prevention.
Authors: Perry N Halkitis; Pamela Valera; Caleb E LoSchiavo; Stephen E Goldstone; Maria Kanztanou; Anthony J Maiolatesi; Danielle C Ompad; Richard E Greene; Farzana Kapadia Journal: AIDS Patient Care STDS Date: 2019-04 Impact factor: 5.078
Authors: Chunqing Lin; Jiri Slama; Paula Gonzalez; Marc T Goodman; Ningshao Xia; Aimée R Kreimer; Ting Wu; Nancy A Hessol; Yurii Shvetsov; Ana P Ortiz; Beatriz Grinsztejn; Anna-Barbara Moscicki; Isabelle Heard; María Del Refugio González Losa; Erna M Kojic; Maarten F Schim van der Loeff; Feixue Wei; Adhemar Longatto-Filho; Zizipho A Mbulawa; Joel M Palefsky; Annette H Sohn; Brenda Y Hernandez; Katina Robison; Steve Simpson; Lois J Conley; Alexandra de Pokomandy; Marianne A B van der Sande; Racheal S Dube Mandishora; Lays P B Volpini; Alessandra Pierangeli; Byron Romero; Timothy Wilkin; Silvia Franceschi; Carmen Hidalgo-Tenorio; Reshmie A Ramautarsing; Ina U Park; Fernanda K Tso; Sheela Godbole; Kathleen W M D'Hauwers; Borek Sehnal; Lynette J Menezes; Sandra A Heráclio; Gary M Clifford Journal: Lancet Infect Dis Date: 2019-06-13 Impact factor: 25.071
Authors: Ross D Cranston; Alex Carballo-Diéguez; Holly Gundacker; Barbra A Richardson; Rebecca Giguere; Curtis Dolezal; Aaron Siegel; Ratiya P KunjaraNaAyudhya; Kailazarid Gomez; Jeanna M Piper; Javier R Lama; Ian McGowan Journal: Int J STD AIDS Date: 2018-10-18 Impact factor: 1.359
Authors: Fernando Dias Gonçalves Lima; Janine D Viset; Mariska M G Leeflang; Jacqueline Limpens; Jan M Prins; Henry J C de Vries Journal: Open Forum Infect Dis Date: 2019-04-16 Impact factor: 3.835
Authors: Yuanfan Ye; Greer A Burkholder; Amrita Mukherjee; Daniel Chu; Anju Bansal; Staci L Sudenga; Anna Junkins; Sameer Al Diffalha; Michael S Saag; Sadeep Shrestha Journal: Infect Agent Cancer Date: 2021-02-17 Impact factor: 2.965
Authors: Elisa M Bolatti; Lea Hošnjak; Diego Chouhy; Pablo E Casal; María F Re-Louhau; Hebe Bottai; Kristina Fujs Komloš; Mario Poljak; Adriana A Giri Journal: BMC Infect Dis Date: 2020-04-07 Impact factor: 3.090